The U of Nebraska recently started a clinical trial to evaluate Gilead's Remdesivir to treat COVID-19, sponsored by the National Institutes of Health (NIH/NIAID).
However, it has not proven to be beneficial yet:
"“We urgently need a safe and effective treatment for COVID-19. Although Remdesivir has been administered to some patients with COVID-19, we do not have solid data to indicate it can improve clinical outcomes,” said NIAID Director and U.S. Coronavirus Task Force member Anthony S. Fauci, M.D."
https://www.nih.gov/news-events/news-releases/nih-clinical-trial-remdesivir-treat-covid-19-begins
Contrast that with Mesoblast's statement today (excerpt):
"Remestemcel-L has potential for use in the treatment of ARDS, which is the principal cause of death in COVID-19
infection. This is supported by recently published results from an investigator-initiated clinical study conducted in
China which reported that allogeneic MSCs cured or significantly improved functional outcomes in all seven treated
patients with severe COVID-19 pneumonia."
My conclusion:
1) Dr. Itescu would not release today's PR unless he is pretty sure Remestemcel-L works. I believe he is not trying to simply get on the COVID-19 cure bandwagon to gain market attention. The man is conservative.
2) Gilead's Remdesivir is unproven so far, from Anthony Fauci's statement.
Advantage Mesoblast.
- Forums
- ASX - By Stock
- MSB
- Gilead vs Mesoblast
MSB
mesoblast limited
Add to My Watchlist
1.30%
!
$2.28

Gilead vs Mesoblast
-
-
- There are more pages in this discussion • 215 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$2.28 |
Change
-0.030(1.30%) |
Mkt cap ! $2.918B |
Open | High | Low | Value | Volume |
$2.32 | $2.39 | $2.24 | $13.10M | 5.680M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 44474 | $2.27 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.29 | 30176 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 44030 | 2.270 |
4 | 31511 | 2.260 |
4 | 12725 | 2.250 |
5 | 28464 | 2.240 |
4 | 30100 | 2.230 |
Price($) | Vol. | No. |
---|---|---|
2.290 | 30176 | 3 |
2.300 | 15322 | 3 |
2.310 | 12000 | 2 |
2.320 | 21980 | 6 |
2.330 | 10410 | 2 |
Last trade - 16.17pm 22/07/2025 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |